Yu Jonathan Yen-Wen 4

4 · Disc Medicine, Inc. · Filed Jun 18, 2026

AI-generated summary of this filing

Updated Jun 18, 2026

Disc Medicine (IRON) COO Jonathan Yen-Wen Sells Shares After Exercising Options

What Happened

Jonathan Yen-Wen, Chief Operating Officer of Disc Medicine (IRON), exercised stock options to acquire 18,612 shares (5,261 + 13,351) at $9.86 per share (total cost $183,514) on June 16, 2026, and sold the same 18,612 shares in open-market transactions the same day for aggregate proceeds of $1,287,801.
The filing shows the option positions were converted (reported as derivative dispositions at $0) and the open-market sales (11,651 shares at a weighted $68.76 and 6,961 shares at a weighted $69.92) completed under a pre-established Rule 10b5-1 trading plan.

Key Details

Transaction date: June 16, 2026; Form 4 filed June 18, 2026 (timely).
Option exercise: 18,612 shares at $9.86 each; total exercise cost $183,514.
Open-market sales: 18,612 shares for total proceeds $1,287,801 (11,651 shares at weighted $68.76, range $68.37–$69.36; 6,961 shares at weighted $69.92, range $69.40–$70.19).
Footnotes: Transactions effected under a Rule 10b5-1 trading plan adopted March 17, 2026. Reporting person will provide breakdown of shares sold at each price on request. Options underlying these shares were fully vested as of the date.
Shares owned after transaction: not specified in the provided filing excerpt.

Context

This was an exercise of vested options followed by immediate open-market sales — a common cashless-exercise pattern where exercised shares are sold to cover exercise cost/taxes or to monetize gains. The use of a 10b5-1 plan indicates the trades were pre-planned and intended to comply with insider trading rules.
These are routine insider sales following option exercises and do not, by themselves, indicate company-wide sentiment.

Form 4

Period: 2026-06-16

Chief Operating Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-16$9.86/sh+5,261$51,873→ 59,585 total
Exercise/Conversion
Common Stock
[F1]
2026-06-16$9.86/sh+13,351$131,641→ 72,936 total
Sale
Common Stock
[F1][F2]
2026-06-16$68.76/sh−11,651$801,102→ 61,285 total
Sale
Common Stock
[F1][F3]
2026-06-16$69.92/sh−6,961$486,699→ 54,324 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-06-16−5,261→ 1,753 total
Exercise: $9.86Exp: 2031-09-13→ Common Stock (5,261 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-06-16−13,351→ 31,951 total
Exercise: $9.86Exp: 2031-09-13→ Common Stock (13,351 underlying)

Footnotes (4)

[F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 to $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.40 to $70.19, inclusive.
[F4]The shares underlying this option are fully vested and exercisable as of the date hereof.

Signature

By: /s/ Rahul Khara, as Attorney-in-Fact|2026-06-18

1 file